Source comparison
Melanotan-1 UV Protection Protocol: Clinical vs Recreational Comparison
Clinical (EPP photoprotection) 0.16mg/kg daily × 14 days 0.16mg/kg every 60 days Maximum pigmentation at 4–6 weeks, sustained with bimonthly dosing Erythropoietic protoporphyria, polymorphous light eruption, solar urticaria Nausea (15%), injection site reactio
This comparison does not assign a generated winner or score.
- Clinical (EPP photoprotection)
- 0.16mg/kg daily × 14 days
- 0.16mg/kg every 60 days
- Maximum pigmentation at 4–6 weeks, sustained with bimonthly dosing
- Erythropoietic protoporphyria, polymorphous light eruption, solar urticaria
- Nausea (15%), injection site reaction (8%), headache (5%)
- FDA-approved under brand name Scenesse for EPP. Highest evidence base for photoprotection efficacy
- Recreational (aesthetic tanning)
- 0.1–0.12mg/kg daily × 10–14 days
- 0.08–0.12mg/kg 2–3× weekly
- Visible tanning at 7–10 days, peak at 3–4 weeks
- Pre-vacation tanning, phototype I–II skin baseline before UV exposure
- Similar to clinical but dose-dependent. Higher maintenance doses increase nausea risk
- Not FDA-approved for cosmetic use. Protocol derived from off-label clinical data
- Minimal Maintenance
- 0.1mg/kg daily × 7 days
- 0.08mg/kg once weekly
- Light pigmentation at 10–14 days, requires UV co-exposure to deepen
- Individuals seeking subtle tan without frequent injections
- Lower nausea incidence due to reduced cumulative dose
- Insufficient for true photoprotection. Best suited for users with phototype III–IV baseline